Dogwood Therapeutics

About Dogwood Therapeutics

Dogwood Therapeutics is a development-stage biotechnology company focused on advancing novel therapeutics for pain and fatigue illnesses. They are pioneering treatments like Halneuron, a selective sodium channel blocker for chemotherapy-induced neuropathic pain (CINP), cancer pain, and other pain indications, as well as antiviral combination therapies (IMC-1 and IMC-2) for diseases like Long COVID and fibromyalgia.

Products & Services

Halneuron:A highly selective sodium channel blocker for treating moderate-to-severe chemotherapy-induced neuropathic pain (CINP), cancer pain, and other pain indications. It shows no evidence of addiction, withdrawal symptoms, or tolerance build-up, with long-lasting pain relief and minimal side effects.

IMC-1 and IMC-2:Antiviral combination therapies being developed to treat diseases associated with viral-triggered abnormal immune responses, such as Long COVID and fibromyalgia.

Halneuron®

Specialties

Pain Management (Non-Opioid) Chemotherapy-Induced Neuropathic Pain (CINP) Long COVID Treatment Fibromyalgia Treatment Antiviral Therapies Sodium Channel Blockers Non-Opioid Pain Management CINP CIPN Fibromyalgia

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Registered Direct Offering and Private Placement T: - FT: Registered Direct Offering and Private Placement	A: 12500000 MR: - FA: $12.5 Million FAN: 12500000	D: 2026-01-12 FD: 2026-01-12	1 investors
2	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 4800000 MR: - FA: $4.8 million FAN: 4800000	D: 2025-03-13 FD: 2025-03-13	1 investors
3	RT: Debt to Equity Conversion T: - FT: Debt to Equity Conversion	A: 19500000 MR: - FA: $19.5M FAN: 19500000	D: 2025-03-12 FD: 2025-03-12	2 investors

Registered Direct Offering and Private Placement Latest

2026-01-12

$12.5M

1 investor (Pro only)

Registered Direct Offering 2025-03-13

$4.8M

Debt to Equity Conversion 2025-03-12

$19.5M

View 2 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

G

Greg Duncan

Chief Executive Officer & Chairman of the Board of Directors

R

R. Michael Gendreau

Chief Medical Officer

R

Ralph Grosswald

Senior Vice President of Operations

A

Angela Walsh

Chief Financial Officer, Secretary & Treasurer

G

Greg Duncan

Chief Executive Officer & Chairman of the Board of Directors

A

Abel De La Rosa

Chairman of the Board of Directors

View 8 more team members with Pro

Unlock Full Team Directory

Recent News